Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD. Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development.read more
In the Bottom 25% of 1836 similar size companies on Comparably
BOTTOM
30%
In the Bottom 30% of 220 companies in Boston
?
Not enough ratings to compare against competitors
Kymera Therapeutics' team score is currently ranked in the Bottom 25% of similar sized companies on Comparably. 63% of Kymera Therapeutics employees look forward to interacting with coworkers while 50% believe their company meetings are effective.
Rate Team the Highest
Not Enough Ratings To Show Who Ranks Team the Highest